Using experimental systems and patient material we study the immune system with a specific interest related to inflammation, autoimmune disease and cancer immunotherapy.
A major part of the different projects in the lab relates to antibodies, neutrophils and T cells. We also spend a lot of effort into using CRISPR/Cas9 based custom screens as a discovery platform to understand complex biological processes and to identify novel drug targets. To facilitate the design of these screens, we have developed a software that we call Green Listed (Panda et al, 2017, Bioinformatics). A blog post describing our approach can be found at Addgene (link).
Currently several projects in the lab relates to our interest in signaling downstream of the IL-4 receptor (IL-4R). The basis for this interest was the unexpected finding that the expression of the IL-4R is essential for the activity of a drug (IVIG) used to treat patients with autoimmune disease, and that the expression of this receptor is highly regulated during inflammation (Anthony et al, 2011, Nature and Wermeling et al, 2013, PNAS).
Other projects are using in vivo CRISPR screens to identify central genes affecting the behavior of T cells and neutrophils in autoimmune disease and cancer.
The Wermeling Laboratory is located at the Center for Molecular Medicine (CMM), Karolinska University Hospital, Solna, Sweden, physically located here. The group is part of the Rheumatology Unit, Department of Medicine, Karolinska Institutet, Solna.
This website is maintained by Fredrik Wermeling. Opinions expressed are the author’s own and does not necessarily reflect the view of the Karolinska Institutet, the Karolinska Hospital, CMM or any other organization mentioned on the website.